To include your compound in the COVID-19 Resource Center, submit it here.

Adcetris brentuximab vedotin: Updated Phase II data

Updated data from a single-arm, open-label, international Phase II trial in 58 patients with relapsed or refractory ALCL showed that brentuximab vedotin led to a median duration of response of 13.2 months in the 57%

Read the full 354 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE